pharmaceutical factory worker

WuXi Biologics, is a leading global open-access biologics technology platform offering end-to-end solutions to empower organisations to discover, develop and manufacture biologics, from concept to commercial production. 

In late 2019, WuXi Vaccines, a WuXi Biologics subsidiary, announced it would invest USD 240 million to build an integrated vaccine manufacturing facility within the WuXi Biologics Campus adjacent to the “Factory of the Future” biologics manufacturing facility, scheduled to begin commercial production in 2021. The vaccine facility will supply vaccine products for a large global pharma company to the global market. 

Actemium Shanghai will handle the design, supply and installation of a complete clean utility system in the new vaccine manufacturing plant (purified water, water for injection, and clean steam for equipment and the clean utility loop), including mechanical, electrical and automation work.

“The main technical challenge of this project will be to create an extremely precise design in China to avoid any problems with the on-site installation in Ireland,” explains Kristien Loontjens, Business Unit Manager at Actemium Shanghai. The works began in August 2020 and will be completed in October 2021.